Search research articles
Contact Us
Filters
Showing results (241-250 of 269) with videos related to
Page
of 27
Sort By:
The New England Journal of Medicine
|
February 5, 2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer
Alison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2024
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer
Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 26, 2021
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions
Sebastian Mondaca, Emily S Lebow, Azadeh Namakydoust, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 9, 2021
Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73]
Sebastian Mondaca, Emily S Lebow, Azadeh Namakydoust, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 16, 2024
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer
Si-Yang Liu, Tatiana Erazo, Justin Jee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2021
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
Zsofia K Stadler, Anna Maio, Debyani Chakravarty, et al.
Cancer Discovery
|
February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2021
Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Alexander Drilon, Michael Duruisseaux, Ji-Youn Han, et al.
The Lancet. Oncology
|
December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Page
of 27
Search research articles
Search
Showing results (241-250 of 269) with videos related to
Sort By:
Page
of 27
The New England Journal of Medicine
|
February 5, 2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer
Alison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2024
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer
Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 26, 2021
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions
Sebastian Mondaca, Emily S Lebow, Azadeh Namakydoust, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 9, 2021
Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73]
Sebastian Mondaca, Emily S Lebow, Azadeh Namakydoust, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 16, 2024
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer
Si-Yang Liu, Tatiana Erazo, Justin Jee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2021
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
Zsofia K Stadler, Anna Maio, Debyani Chakravarty, et al.
Cancer Discovery
|
February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2021
Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Alexander Drilon, Michael Duruisseaux, Ji-Youn Han, et al.
The Lancet. Oncology
|
December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Page
of 27